Network meta-analysis demonstrates safety profile of DAR + ADT in metastatic castration-sensitive prostate cancer, suggesting effective management options.
This NMA supports the superior efficacy of ARPI combinations against ADT monotherapy, for both OS and PFS. While DAR + ADT demonstrated comparable efficacy to other doublet combinations, it offered a superior safety profile, making it an effective and safe option for managing patients with mCSPC.
No takes yet. Share an insight, caveat, or question.
Shore et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: